- Conditions
- Chronic Heart Failure With Reduced Systolic Function
- Interventions
- Dapagliflozin, Dapagliflozin matching placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 19 Years to 119 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 25
- States / cities
- Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 51
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo-matching dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
- Conditions
- Diabetic Kidney Disease
- Interventions
- MEDI3506, Placebo, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo matching Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 12
- States / cities
- Chula Vista, California • San Diego, California • Torrance, California + 9 more
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 6,263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 66
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 86
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Baxdrostat/Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Surprise, Arizona • Hollywood, Florida • Port Charlotte, Florida + 14 more
- Conditions
- Heart Failure
- Interventions
- Baxdrostat and dapagliflozin, Placebo and dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 176 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 60
- States / cities
- Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Kidney Disease
- Interventions
- Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more
- Conditions
- Type 2 Diabetes Mellitus, CKD and Albuminuria
- Interventions
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • Chula Vista, California • Concord, California + 34 more
- Conditions
- Acute Heart Failure, Heart Failure
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The TIMI Study Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Tempe, Arizona • Encino, California • Fresno, California + 24 more
- Conditions
- Heart Failure, Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New Orleans, Louisiana • Philadelphia, Pennsylvania
- Conditions
- Chronic Heart Failure With Preserved Systolic Function
- Interventions
- Dapagliflozin 10Mg Oral Tablet, Dapagliflozin matching placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 19 Years to 119 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 21 more
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Placebo/dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 133
- States / cities
- Fairhope, Alabama • Surprise, Arizona • Tucson, Arizona + 117 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo matching Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 40
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- COVID-19
- Interventions
- Dapagliflozin 10 milligram (mg), Placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more